Lien Lybaert

myNEO Therapeutics has developed a proprietary, best-in-class AI-powered platform technology for target discovery fueling breakthrough immunotherapy. myNEO is now bringing novel, proprietary, best-in-class tumor targets, called camyotopes, to the clinic.